• Jinglei Liu, Kai Zhang, Xiaolong Wu, Bao Cui, and Zhihui Liang.
• Department of Interventional Treatment, 980 Hospital of PLA Joint Logistics Support Forces (Bethune International Peace), Shijiazhuang, China.
• Medicine (Baltimore). 2022 Nov 18; 101 (46): e31595e31595.

BackgroundIncreasing evidence supports the efficacy and safety of prostatic artery embolization (PAE) in the treatment of benign prostatic hyperplasia. However, PAE relies on ionizing radiation, which has not been studied systematically so far. Therefore, the potential associated risks remain largely unknown and are subject to intense debate. We performed a protocol for systematic review and meta-analysis to evaluate the clinical benefits of different radiation doses in patients with benign prostatic hyperplasia undergoing PAE.MethodsA comprehensive search of several databases from 1966 to October 2022 was conducted. The databases include Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid PsycINFO, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and PubMed. Risk of bias of the included studies was assessed by the "Risk of Bias Assessment Tool" of the Cochrane Handbook for randomized controlled trials. All data were analyzed using the Comprehensive Meta-Analysis software package (Biostat, Engelwood, NJ).ResultsThe results will be submitted to a peer-reviewed journal once completed.ConclusionThis review will provide reliable evidence for extensive application of PAE for benign prostatic hyperplasia and determine the most rational radiation dose for these patients.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

16 keywords...

hide…